Literature DB >> 16288821

Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells.

Ying Waeckerle-Men1, Edith Uetz-von Allmen, Bruno Gander, Elke Scandella, Eva Schlosser, Gunter Schmidtke, Hans P Merkle, Marcus Groettrup.   

Abstract

Dendritic cell (DC)-based immunotherapy has been hampered by the lack of suitable methods for antigen delivery. Here, we use biodegradable poly(D,L-lactide-co-glycolide) microspheres (PLGA-MS) as carriers of peptides and proteins for antigen delivery to human monocyte-derived DC (MoDC). Compared to soluble proteins, MHC classes I and II-restricted presentation of PLGA-MS-encapsulated proteins and peptides by MoDC was markedly prolonged and proteins were presented 50-fold more efficiently on class I molecules. The vaccination of mice with DC loaded with PLGA-MS-encapsulated proteins raised strong and persisting cytotoxic T cell responses. In conclusion, antigen delivery via PLGA-MS markedly enhanced the duration of antigen presentation by human MoDC and the potency of DC-based vaccination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288821     DOI: 10.1016/j.vaccine.2005.10.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Pivotal advance: peritoneal cavity B-1 B cells have phagocytic and microbicidal capacities and present phagocytosed antigen to CD4+ T cells.

Authors:  David Parra; Aja M Rieger; Jun Li; Yong-An Zhang; Louise M Randall; Christopher A Hunter; Daniel R Barreda; J Oriol Sunyer
Journal:  J Leukoc Biol       Date:  2011-11-04       Impact factor: 4.962

2.  Quantitative aspects of intracellularly-targeted drug delivery.

Authors:  David Stepensky
Journal:  Pharm Res       Date:  2010-09-02       Impact factor: 4.200

Review 3.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

Review 4.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

5.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Authors:  Shailendra B Tallapaka; Bala V K Karuturi; Pravin Yeapuri; Stephen M Curran; Yogesh A Sonawane; Joy A Phillips; D David Smith; Sam D Sanderson; Joseph A Vetro
Journal:  Int J Pharm       Date:  2019-05-08       Impact factor: 5.875

6.  Alginate-chitosan-PLGA composite microspheres enabling single-shot hepatitis B vaccination.

Authors:  Xiaoling Zheng; Yongzhuo Huang; Caihong Zheng; Siyu Dong; Wenquan Liang
Journal:  AAPS J       Date:  2010-06-25       Impact factor: 4.009

7.  In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines.

Authors:  Jaeyun Kim; David J Mooney
Journal:  Nano Today       Date:  2011-10       Impact factor: 20.722

8.  PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival.

Authors:  Kevin P Nikitczuk; Rene S Schloss; Martin L Yarmush; Edmund C Lattime
Journal:  J Cancer Ther       Date:  2013-01-01

9.  Active self-healing encapsulation of vaccine antigens in PLGA microspheres.

Authors:  Kashappa-Goud H Desai; Steven P Schwendeman
Journal:  J Control Release       Date:  2012-10-24       Impact factor: 9.776

Review 10.  Current advances in research and clinical applications of PLGA-based nanotechnology.

Authors:  Jian-Ming Lü; Xinwen Wang; Christian Marin-Muller; Hao Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2009-05       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.